This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
NCT07121946
Recruiting
This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a single agent in adult subjects with relapsed or refractory B-cell non-Hodgkin lymphoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: Tennessee Oncology, Nashville, Tennessee
Conditions: Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL)
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
08/20/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +534 locations
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
Neurophysiology Biomarkers of Cognitive Impairment Associated With Deep Brain Stimulation
NCT05933681
Recruiting
The study aims to investigate cognitive impairment associated with Deep Brain Stimulation (DBS) in Parkinson's Disease patients, with a focus on identifying neurophysiology biomarkers of DBS associated cognitive changes. Using neurophysiology data recorded during DBS surgeries and post-implantation, the research intends to identify biomarkers in order to optimize electrode placement, enhance programming, and ultimately minimize DBS-related cognitive side effects.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/20/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Parkinson Disease
Register for Updates
Comparison of Body Composition Changes With Weight Loss Interventions
NCT07115069
Recruiting
This study is being done to compare the effects of a newer class of weight loss medications to weight loss surgery on the body's muscle, metabolism, and side effects over time. People with severe obesity often lose weight using either medications like GLP-1 receptor agonists (such as semaglutide or tirzepatide) or by having bariatric surgery, such as gastric bypass. While both approaches can lead to weight loss, they may affect the body in different ways. The investigators are inviting adult pa... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
08/20/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Obesity
Register for Updates
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601
Recruiting
The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced breast, colorectal, prostate, and endometrial cancer. This is a 2-part study. Participation could last up to 36 weeks or until your tumor progresses.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: University of California, Los Angeles (UCLA), Los Angeles, California +10 locations
Conditions: Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms, Neoplasm Metastasis
Register for Updates
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors
NCT05687136
Recruiting
This phase I trial tests the safety, side effects and best dose of peposertib (M3814) in combination with tuvusertib (M1774) in treating patients with solid tumors that have spread to other places in the body (advanced). Peposertib and tuvusertib stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland +5 locations
Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Register for Updates
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
NCT05653349
Recruiting
The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count ≥30 G/L in adult participants with primary ITP.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/20/2025
Locations: Yuma Regional Medical Center, Yuma, Arizona +154 locations
Conditions: Primary Immune Thrombocytopenia (ITP)
Register for Updates
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
NCT05921253
Recruiting
This study is to determine if low level vagus nerve stimulation will lead to improvement in heart function, heart rate variation, and in the levels of certain chemical markers of inflammation in study participants' blood.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/20/2025
Locations: Stephenson Cancer Center, Oklahoma City, Oklahoma +1 locations
Conditions: Breast Cancer, Lymphoma
Register for Updates
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
NCT06072482
Recruiting
The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/20/2025
Locations: Orthopedic Physicians Alaska, Anchorage, Alaska +54 locations
Conditions: Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Register for Updates
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Early-Line Treatment in Subjects With Multiple Myeloma
NCT07073547
Recruiting
This trial is a phase 1, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CAR T-cell therapy, in early-line treatment in subjects with Multiple Myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: Research Site, Duarte, California +5 locations
Conditions: Newly Diagnosed Multiple Myeloma, Relapsed Refractory Multiple Myeloma
Register for Updates
A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
NCT06149286
Recruiting
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called "relapsed"), or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's lymphoma (NHL). This study will be made up of two parts (Part 1 not randomized, Part... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: David Geffen School of Medicine at UCLA, Los Angeles, California +148 locations
Conditions: Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL)
Register for Updates
Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition
NCT06094478
Recruiting
Most stroke patients are initially evaluated at the closest hospital but some need to be transferred to a hospital that can provide more advanced care. The "Door-In-Door-Out" (DIDO) process at the first hospital can take time making transferred patients no longer able to get the advanced treatments. This study will help hospitals across the US "stand up" new ways to evaluate stroke patients, decide who needs to be transferred, and transfer them quickly for advanced treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut +6 locations
Conditions: Stroke, Acute, Ischemic Stroke, Acute, Hemorrhagic Stroke
Register for Updates